Citi analyst Joel Beatty lowered his price target for Sarepta Therapeutics to $190 from $201 citing risk to the company's lead on all gene therapy programs while manufacturing ramps up. The analyst, however, says his base case remains that Sarepta will continue to get more credit for its gene therapy pipeline over the 12 months as additional LGMD data is generated. He now believes that it is more likely than not that both exon 53 skipping agent Golodirsen and exon 45 skipping agent Casimersen will be approved in Duchenne muscular dystrophy. Beatty keeps a Buy rating on Sarepta.